Third party funded individual grant
Acronym: TR-Platelet Hemostasis
Start date : 01.05.2022
End date : 30.04.2023
Immune checkpoint inhibitors (ICIs) have revolutionized classical approaches to the treatment of various cancer entities, but are also associated with a number of side effects. One of these may be life-threatening clotting disorders with risk of thrombotic or hemorrhagic complications, the mechanisms of which are still poorly understood. In the present study, we analyze the direct effects of pembrolizumab, nivolumab and ipilimumab on platelet aggregation as well as plasma coagulation followed by fibrinolysis in an ex vivo model.